Autonomic Disorders Certification Examination Committee Contributors
Elizabeth Coon, MD, Chair, Mayo Clinic – Rochester
Disclosures: Nothing to disclose.
Satish Raj, MD, Vice Chair, University of Calgary
Disclosures: Received personal compensation for serving as a consultant to: Theravance Biopharma – nOH Consulting; Amneal Pharma – nOH Consulting; Servier Affaires Medicales – POTS Consulting; Regeneron – POTS Consulting; Argenx BV – POTS Consulting; Antag Pharma – POTS Consulting; received personal compensation for serving as an editor: Autonomic Neurosciences: Basic & Clinical (Elsevier) [ME]; received research support from Canadian Institutes of Health Research, Heart & Stroke Foundation of Canada, Dysautonomia International, and Standing Up To POTS; within the past two years served as American Autonomic Society – Past President (no financial compensation).
Srikanth Muppidi, MD, Stanford Neuroscience Health Center
Disclosures: Received personal compensation for serving on a scientific advisory or data safety monitoring board for Alexion, argenx, UCB/Ra pharma, and Horizont Pharma.
Melissa M. Cortez, DO, University of Utah Health
Disclosures: Currently serves on the DSMB for the RECOVER CT, which is NIH funded; received research funding from the NIH NINDS (K23, R21, R61), Amgen (Young Investigator Award), and Dysautonomia Int’l.
Elisabeth Golden, MD, UT Southwestern
Disclosures: Within the past two years received research support (grant for salary support) from the nonprofit Ware Fund while at UT Southwestern, 2020-2022, total of $50,000; received honoraria from The Dysautonomia Project for serving as faculty for The Residents Course 1/2023, and upcoming speaking at patient course Dyscourse, total $2500 and reimbursement of travel expenses to the events.
Nathaniel Robbins, MD, Mass General/Brigham and Women's
Disclosures: Received personal compensation for Market research consulting: Guidepoint Global Consulting, TDG health, and Alpha detail; received personal compensation for serving as an expert witness for the Department of Justice and DHHS; received research support for work on Ethnoinstitute, Dysautonomia Project - Dysautonomia International, Reeves Foundation, and Diamond Foundation.
Howard Snapper, MD, WellStar Medical Group
Disclosures: Nothing to disclose.
Kamal Shouman, MD, Mayo Clinic – Rochester
Disclosures: Own stock or an ownership interest (excluding mutual funds) from/with a commercial interest greater than 5 percent of the company or greater than $10,000 in value (whichever dollar value is lowest): Apple stock.
Amanda Peltier, MD, Vanderbilt University Medical Center
Disclosures: Received personal compensation from Alnylam- consultant and independent speaker; served on advisory board AstraZeneca, consultant and independent speaker; served on advisory board CSL Behring, research support for investigator-initiated research in CIDP; received personal compensation for serving on a speakers bureau for Alnylam and AstraZeneca; received personal compensation for serving on the board of directors, and am president elect of the American Autonomic Society; received personal compensation for providing expert opinion in a legal case involving Merck pharmaceutical; received research support as an investigator-initiated research project through CSL Behring. Dr. Peltier is NIH funded and serves as local site investigator for a study based at Massachusetts General Hospital (Healey, non-profit); she is the local site investigator for a Alexion study; participated as a member of an examination development or certification examination review course committee for ABPN Neuromuscular board committee (resigned 2 years ago to comply for this board/committee).
Gisela G. Chelimsky, MD, Virginia Commonwealth University
Disclosures: Received personal compensation from ABP Pediatric GI certification exam committee for reviewing and writing questions; Co-owner of PainSTakers LLC, but receive no compensation; Within the past two years received research support from NIH.